Predictive factors of overall functioning improvement in patients with chronic schizophrenia and schizoaffective disorder treated with paliperidone palmitate and aripiprazole monohydrate

Background Long‐acting injectable (LAI) antipsychotics can improve medication adherence and reduce hospitalisation rates compared with oral treatments. Paliperidone palmitate (PAL) and aripiprazole monohydrate (ARI) LAI treatments were associated with improvements in global functioning in patients w...

Full description

Saved in:
Bibliographic Details
Published in:Human psychopharmacology 2018-05, Vol.33 (3), p.e2658-n/a
Main Authors: Girardi, Paolo, Del Casale, Antonio, Rapinesi, Chiara, Kotzalidis, Georgios D., Splendori, Francesca, Verzura, Claudio, Trovini, Giada, Sorice, Serena, Carrus, Dario, Mancinelli, Iginia, Comparelli, Anna, De Filippis, Sergio, Francomano, Antonio, Ballerini, Andrea, Marcellusi, Andrea, Mennini, Francesco S., Ducci, Giuseppe, Sani, Gabriele, Pompili, Maurizio, Brugnoli, Roberto
Format: Article
Language:English
Subjects:
Adult
Antipsychotic Agents - administration & dosage
Antipsychotic Agents - pharmacology
Antipsychotics
Aripiprazole
Aripiprazole - administration & dosage
Aripiprazole - pharmacology
aripiprazole monohydrate
Delayed-Action Preparations
Female
Females
global assessment of functioning
Humans
long‐acting injectable antipsychotics
Male
Males
Mental disorders
Middle Aged
Outcome Assessment (Health Care)
paliperidone palmitate
Paliperidone Palmitate - administration & dosage
Paliperidone Palmitate - pharmacology
Palmitic acid
Patients
Psychotic Disorders - drug therapy
Schizoaffective disorder
Schizophrenia
Schizophrenia - drug therapy
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Long‐acting injectable (LAI) antipsychotics can improve medication adherence and reduce hospitalisation rates compared with oral treatments. Paliperidone palmitate (PAL) and aripiprazole monohydrate (ARI) LAI treatments were associated with improvements in global functioning in patients with schizophrenia. Objective The objective of this study was to assess the predictive factors of better overall functioning in patients with chronic schizophrenia and schizoaffective disorder treated with PAL and ARI. Method Enrolled were 143 (97 males, 46 females, mean age 38.24 years, SD = 12.65) patients with a diagnosis of schizophrenia or schizoaffective disorder, whom we allocated in two groups (PAL and ARI treatments). We assessed global functioning, amount of oral medications, adherence to oral treatment, and number of hospitalisations before LAI introduction and at assessment time point. Results Longer treatment time with LAIs (p 
ISSN:0885-6222
1099-1077
DOI:10.1002/hup.2658